[
    [
        {
            "time": "2018-06-05",
            "original_text": "Health Care Sector Update for 06/05/2018: MYL,VKTX,PLX,LLY",
            "features": {
                "keywords": [
                    "Health",
                    "Care",
                    "Sector",
                    "Update",
                    "MYL",
                    "VKTX",
                    "PLX",
                    "LLY"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 06/05/2018: MYL,VKTX,PLX,LLY",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp.",
            "features": {
                "keywords": [
                    "Lilly",
                    "Shareholders",
                    "Reject",
                    "Below-Market",
                    "Mini-Tender",
                    "Offer",
                    "TRC",
                    "Capital",
                    "Corp."
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp.",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Health Care Sector Update for 06/05/2018: VKTX,PLX,LLY",
            "features": {
                "keywords": [
                    "Health",
                    "Care",
                    "Sector",
                    "Update",
                    "VKTX",
                    "PLX",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 06/05/2018: VKTX,PLX,LLY",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Merck Presents Positive Melanoma Data on Keytruda at ASCO",
            "features": {
                "keywords": [
                    "Merck",
                    "Positive",
                    "Melanoma",
                    "Data",
                    "Keytruda",
                    "ASCO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck Presents Positive Melanoma Data on Keytruda at ASCO",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial",
            "features": {
                "keywords": [
                    "DDW",
                    "2018",
                    "Patients",
                    "Moderate-to-Severe",
                    "Ulcerative",
                    "Colitis",
                    "Clinical",
                    "Endoscopic",
                    "Remission",
                    "Mirikizumab",
                    "Phase",
                    "2",
                    "Trial"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Health Care Sector Update for 06/05/2018: PLX, VKTX, LLY",
            "features": {
                "keywords": [
                    "Health",
                    "Care",
                    "Sector",
                    "Update",
                    "PLX",
                    "VKTX",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 06/05/2018: PLX, VKTX, LLY",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "FDA Expands Lilly's ALIMTA速 (pemetrexed) Label to Include Combination with KEYTRUDA速 (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression",
            "features": {
                "keywords": [
                    "FDA",
                    "Expands",
                    "Lilly's",
                    "ALIMTA",
                    "Label",
                    "Include",
                    "Combination",
                    "KEYTRUDA",
                    "Carboplatin",
                    "First-Line",
                    "Treatment",
                    "Metastatic",
                    "Nonsquamous",
                    "Non-Small",
                    "Cell",
                    "Lung",
                    "Cancer",
                    "PD-L1",
                    "Expression"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA Expands Lilly's ALIMTA速 (pemetrexed) Label to Include Combination with KEYTRUDA速 (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Eli Lilly: FDA Expands ALIMTA Label To Include Combination With KEYTRUD",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "FDA",
                    "Expands",
                    "ALIMTA",
                    "Label",
                    "Include",
                    "Combination",
                    "KEYTRUD"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly: FDA Expands ALIMTA Label To Include Combination With KEYTRUD",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]